MARKET

ZNTL

ZNTL

Zentalis Pharmaceuticals, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

58.05
+2.20
+3.93%
Opening 10:09 04/23 EDT
OPEN
55.99
PREV CLOSE
55.85
HIGH
58.33
LOW
55.64
VOLUME
38.92K
TURNOVER
--
52 WEEK HIGH
61.29
52 WEEK LOW
25.41
MARKET CAP
2.38B
P/E (TTM)
-18.9226
1D
5D
1M
3M
1Y
5Y
Gain Therapeutics inks multi-target drug discovery collaboration agreement with zentalis
Gain Therapeutics ([[GANX]]) announces a multi-target collaboration agreement with Zentalis Pharmaceuticals ([[ZNTL]] -0.7%) to discover new product candidates for the treatment of cancer.Under the terms of the agreement, Gain will pursue binding
Seekingalpha · 3d ago
DJ Gain Therapeutics in Collaboration Agreement With Zentalis Pharma
Dow Jones · 3d ago
Gain Therapeutics Announces Multi-Target Drug Discovery Collaboration Agreement With Zentalis Pharmaceuticals; Financial Details Not Disclosed
Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain") today announced a multi-target collaboration agreement with Zentalis Pharmaceuticals (NASDAQ:ZNTL) to discover new product candidates for the treatment of cancer.
Benzinga · 3d ago
Gain Therapeutics Forms Multi-Target Drug Discovery Partnership with Zentalis Pharmaceuticals
MT Newswires · 3d ago
DJ Zentalis Pharmaceuticals Is Maintained at Outperform by SVB Leerink
Dow Jones · 04/13 10:32
DJ Zentalis Pharmaceuticals Price Target Raised to $64.00/Share From $60.00 by SVB Leerink
Dow Jones · 04/13 10:32
Zentalis surges on clinical collaboration with GlaxoSmithKline
Zentalis Pharmaceuticals ([[ZNTL]] +6.8%) is on the rise in the morning hours after announcing a clinical collaboration agreement with GlaxoSmithKline ([[GSK]] -1.4%).The partnership will involve a study to evaluate the combination of
Seekingalpha · 04/12 15:19
Zentalis's Early WEE1 Inhibitor Data Shows 'Exceptional' Response In Solid Tumor Study, Plans Combination Trials
Benzinga · 04/12 15:18
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ZNTL. Analyze the recent business situations of Zentalis Pharmaceuticals, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ZNTL stock price target is 66.50 with a high estimate of 75.00 and a low estimate of 63.00.
EPS
Institutional Holdings
Institutions: 111
Institutional Holdings: 37.68M
% Owned: 91.80%
Shares Outstanding: 41.04M
TypeInstitutionsShares
Increased
41
8.21M
New
47
847.49K
Decreased
13
1.89M
Sold Out
6
1.68M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.29%
Pharmaceuticals & Medical Research
+0.34%
Key Executives
Chairman/President/Chief Executive Officer/Executive Director
Anthony Sun
Co-Founder/Chief Operating Officer
Kevin Bunker
Chief Financial Officer
Melissa Epperly
Senior Vice President
Peter Huang
Senior Vice President
Ahmed Samatar
Senior Vice President
Dimitris Voliotis
Vice President - Operations
Orna Bornstein
Vice President/General Counsel
Kimberley Overs
Vice President
Meena Rao
Other
Lawrence Cripe
Other
Alexis Pinto
Director
Cam Gallagher
Director
Dave Johnson
Director
Enoch Kariuki
Independent Director
Kimberly Blackwell
Independent Director
David Johnson
Independent Director
Karan Takhar
No Data
About ZNTL
Zentalis Pharmaceuticals, Inc., formerly Zentalis Pharmaceuticals LLC., is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics targeting fundamental biological pathways of cancers. It is developing a pipeline of product candidates with a focus on validated oncology targets. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader. ZN-c5 is in a Phase I/II clinical trial for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative. Its other products include ZN-c3, an oral and small molecule inhibitor of WEE1, a protein tyrosine kinase. ZN-c3 is in a Phase I/II clinical trial for the treatment of advanced solid tumors; ZN-d5, a selective inhibitor of B-cell lymphoma 2, in development for the treatment of hematological malignancies; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, in a Phase I/II clinical trial for the treatment of cell lung cancer.

Webull offers kinds of Zentalis Pharmaceuticals Inc stock information, including NASDAQ:ZNTL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZNTL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ZNTL stock methods without spending real money on the virtual paper trading platform.